대한뉴팜

Daehan New Pharm continues to broaden its growth momentum through consistent sales expansion of its core products.

- Sales up 24.4% and operating profit up 43.4% year-on-year

- Expansion of injectable production lines to meet market demand

- Full-scale operation of the cell culture media production line

Daehan New Pharm’s growth trajectory is accelerating.

In 2014, the company recorded cumulative sales of 51.93 billion KRW, up 24.4% from the same period of the previous year; operating profit reached 5.86 billion KRW, a 43.4% increase; and ordinary profit rose by 117% to 3.62 billion KRW. For the third quarter alone, sales increased 28.8% and operating profit jumped 49% year-on-year, maintaining solid growth every quarter. As a result, the company’s debt-to-sales ratio improved by 18.2 percentage points, and days sales outstanding (DSO) were reduced by 55 days.

Notably, both sales and operating profit are gaining growth momentum compared to the previous year, alongside continued improvement in financial soundness and operational stability.

Guided by its corporate mission of contributing to a healthy life, a happy society, and a sense of warmth, Daehan New Pharm is continuously creating value innovation through a focus on fundamentals, strengthening of core competencies, cash flow-oriented management, proactive risk control, launch of leading products, expansion of distribution coverage through creative solution-based sales, and human-centered management.

To further foster growth in the wellness business segment, the company completed construction of its new injectable production line, enabling stable supply of ampule and vial injections to meet increasing market demand. Meanwhile, to secure future growth drivers, it has completed a facility capable of producing 350,000 liters per month of cell culture media during the first half of the year. The plant has now entered full-scale operation with sales, production, and R&D activities underway, and began supplying domestically produced media to bio companies from the third quarter.